Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Clorox Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Clorox Co trades at $106.8 (market cap $13.09B). The key difference: Clorox Co is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and Clorox Co pays a 4.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CLX | |
|---|---|---|
Market Cap | $5.07B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $127.16 |
52-Week Low | $20.06 | $86.12 |
Enterprise Value | $4.19B | $18.47B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Clorox (CLX) trades at $107.70, up 2.43% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations, though Q4 2025 missed. The company maintains solid profitability with a net margin of 8.74% and ROE of 285.64%, but faces high P/B of 145.45. News highlights Q4 sales beat and a dividend increase to $1.25 per share, while inflation and consumer value-seeking pose challenges.
Outlook is mixed: improving market share and strategic initiatives support growth, but inflation and competitive pressures risk margins. Analyst consensus is cautious with a hold-heavy rating and $97.50 price target below current levels. Key risks include supply-chain inflation and weak organic sales, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
